Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
Make what you want of the Twitter posts of Vlad. But I know for a fact he was discussing the grind and grief he experienced developing the science and growing the company LONG before it was listed or we even knew it existed. He wasn't making a dig at investors or his team. He was saying those very early days would have been much easier if he had a team and long-sighted investors i.e. if you don't start from scratch with $100 and half a good idea like he's managed. He's obviously not done it alone and he doesn't pretend any different. Read the post he was replying to properly, and with this context what he's saying makes total sense. A lot has been made of nothing here and I fell foul of it at first, but it's simply not true. Big misunderstanding.
Try not to fret about price movements at the minute. Accept the ****ty feeling of where we are share price wise. It's been a tough year. But the science has kept rolling and will continue to do so. Pharma is long term and we have plenty of good products, working with good folk, with the clear potential to save lives. Stay safe folks.
P.s. good article here, see if you recognise any names mentioned and their recent success :) do they ring any bells?
https://www.prnewswire.com/news-releases/carisma-therapeutics-presents-data-from-phase-i-clinical-trial-of-ct-0508-a-her2-targeted-car-macrophage-301421642.html
Make what you want of the Twitter posts of Vlad. But I know for a fact he was discussing the grind and grief he experienced developing the science and growing the company LONG before it was listed or we even knew it existed. He wasn't making a dig at investors or his team. He was saying those very early days would have been much easier if he had a team and long-sighted investors i.e. if you don't start from scratch with $100 and half a good idea like he's managed. He's obviously not done it alone and he doesn't pretend any different. Read the post he was replying to properly, and with this context what he's saying makes total sense. A lot has been made of nothing here and I fell foul of it at first, but it's simply not true. Big misunderstanding.
Try not to fret about price movements at the minute. Accept the ****ty feeling of where we are share price wise. It's been a tough year. But the science has kept rolling and will continue to do so. Pharma is long term and we have plenty of good products, working with good folk, with the clear potential to save lives. Stay safe folks.
P.s. good article here, see if you recognise any names mentioned and their recent success :) do they ring any bells?
https://www.prnewswire.com/news-releases/carisma-therapeutics-presents-data-from-phase-i-clinical-trial-of-ct-0508-a-her2-targeted-car-macrophage-301421642.html
Personally don't see Vlad taking another drawdown. Mint with approx 9.5m left to convert. Assuming they're not bought out of that position, we have the money to take CAR-T and CDX through Phase I as it stands. Two products that will likely be worth Bns if successful. Agreed there is more risk now, but an undeniable higher reward. It's a long termer now as I see it. There may well be big things that come up in the next few months with respect to J&J and equally the work that's been done on CBR. Not sure what else to say. If there's a billion shares in issue and HEMO pull off CDX and CAR-T at proof of concept, then we're talking £'s take over at fair value. It's just it's really f'in uncomfortable right now
Welcome (back) to Hemo. Don't bring your logic here, it's not worth anything
Have a day off Micky. Go outside and have a solero.
There are a lot of potential forms that "deals" can take in this area. Find it likely that in the medium-long term, these deals can be worth $100's Millions in milestones, ignoring any potential upfront payments. On the other hand it could be that Vlad negotiates for continued development of the asset, with no transactions taking place at this stage. The more Hemo do for themselves here, the more value they see long-term. All risk-reward.
Please. All. Try to not sound quite so tragic. Read the company prospectus and previous RNS'. You're crying into the void of LSE and only getting the same response back. Log off this dogs4it3 site and stop listening to faceless people on this board. Think for yourself, quietly act or don't act upon those reflections and continue to live your life.
Thank you.
There is zero reason for Mint to short Hemo. It's not in their financial or reputational interest. It's not them shorting, it's a handful of committed PI's who will burn out sooner or later, either with lack of funds or news that closes their positions either by mechanics or panic. It's mega frustrating to see us down here. We bounced of this level back in May/June time, despite being half the company we are now. It'll work out, just come back another day.
Don't reply to people like that with that subject line. You're inadvertently propagating bs
Hemo will never make money. It is explicitly stated in the prospectus that Hemo don't intend to create marketable drugs. They want as many drugs to have passed Proof of Concept (Phase 1/2a) as possible. That's when they're often worth licensing off to majors for silly amounts of money.
However, agree that there are some holes on the Hemo website that could do with plugging - just another example of where the PR work is below an acceptable standard, but we know that's the case here unfortunately. So long as the science continues to be impressive then we'll eventually get the gains we deserve here
hahahaha
The fall for the last 6 months lol. This company is DISGUSTINGLY undervalued
Fair comment Jacko :) agree a catalyst is needed to get out of a 8-10p range. But I'm happy to wait, it's clear Vlad knows how he's going to spend his dosh
Negligible is probably the way to put it!
The company's science and cash situation has never looked better. Sentiment from long termers here is v good, wider (v short term) sentiment poor. We're going to clinical trials imminently with CAR-T and have the money necessary to send CDX off with GlobalCo when they take their thumb out of their arse. Company is on the brink of being CLINICAL, not pre-clinical. I'm shocked the price is this low. I'm an LTH, and I'm never going to tell you not to buy - but for real: this company, at this price, at this juncture, is a no-brainer buy imo.
Don't do anything on emotion today all. SP going down isn't nice for anyone. Gotta chill. Think about why these things are happening. Come back Monday with a clear head and smart attitude :)
You do all realise that this finance package is totally independent of the potential, yet likely deal with GlobalCo? Vlad is getting this money so that we don't have to waste 2021 waiting for Lilly. They're a monster. Those deals take time. We can get underway under our own steam in the meantime.
What do you want them to say? We're going to execute for £12m at 8.316 pence? They can't tell you the execution price. Because it's not decided until the night before being executed. They can only tell you the legal line. Can you cease to be dumb please? It's irritating.
It was also outlined in exactly the same way in the previous RNS. The only thing new in this RNS is that Vlad gets £12m in his hands come Weds next week. CAR-T to phase 1. CDX negotiations ongoing.
And that's for the full £60m. It's not going to happen, just a legal clarification.